NCT02892695 - PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

September 30, 2018

Study Completion Date

September 30, 2019

Conditions

Acute Lymphocytic LeukemiaChronic Lymphocytic LeukemiaFollicular LymphomaMantle Cell LymphomaB-cell Prolymphocytic LeukemiaDiffuse Large Cell Lymphoma

Interventions

BIOLOGICAL

anti-CD19 CAR-NK cells

The allogeneic NK cells (NK-92 cell line for clinical use) are engineered to contain anti-CD19 attached to TCRzeta, CD28 and 4-1BB signaling domains. These modified cells are called chimeric antigen receptor NK cells with specificity for CD19.

Trial Locations (1)

215123

RECRUITING

PersonGen BioTherapeutics (Suzhou) Co., Ltd., Suzhou